Slug: /nz-psychedelic-medicine-regulation
Description: New Zealand now permits psilocybin-assisted therapy outside clinical trials. Here’s what the regulatory landscape looks like in 2026 and what it means for practitioners.
In June 2025, New Zealand’s Ministry of Health quietly marked a historic milestone: a Christchurch psychiatrist received the country’s first approval to prescribe medicinal psilocybin outside of a research setting. This long overdue moment marked Aotearoa’s entry into a small but fast-growing group of countries where psychedelic-assisted therapy is now a clinical reality.
If you work in mental health, medicine, or allied health, understanding the current regulatory environment is essential. Here’s where things stand.
Psilocybin remains a Class A controlled drug under the Misuse of Drugs Act 1975, the most restrictive classification in New Zealand’s drug scheduling system. It also doesn’t have any approved medicines registered with Medsafe, which means that it hasn’t been formally assessed for safety and efficacy through the standard medicine approval process.
This classification hasn’t changed. What has changed is the pathway to legal clinical use.
The legal mechanism that enables psilocybin prescribing is Regulation 22 of the Misuse of Drugs Regulations 1977. This provision allows the Director-General of Health to grant individual practitioners authority to prescribe, supply, and administer certain controlled drugs for defined clinical purposes, all outside of research settings.
In practice, this functions as a special access scheme. It’s not a blanket rescheduling of the substance, and it’s not a clinical trials requirement. Instead, each practitioner must apply individually to Medsafe for approval.
On 24 July 2025, Medsafe published its official guidelines for these applications, the framework that will govern how the field develops in New Zealand for the foreseeable future.
Medsafe assesses applications across four domains: